Medicines can provide significant therapeutic benefits, but their use may also be associated with unintended medical events. Detecting, documenting, and evaluating these events is therefore a continuous responsibility. At the heart of this process is the drug safety database. It’s a structured repository for collecting, managing, assessing, and reporting adverse events and adverse drug reactions.
An adverse drug reaction does not necessarily prove that a particular medicine caused the medical occurrence. The relationship is suspected or considered at least a reasonable possibility. These may include the patient’s medical history, concomitant medicines, treatment exposure, and the timing of the event.
What is a drug safety database?
A drug safety database is a central repository for collecting, evaluating, and managing safety data related to drugs. In pharmacovigilance, adverse events can be characterised according to several dimensions, including seriousness, expectedness, and causal relationship. These characteristics help determine how an individual case is assessed and whether additional regulatory action or reporting requirements apply. Safety databases are pivotal components of pharmacovigilance and used by pharmaceutical companies, MAHs, and CROs.
Safety databases collect data from various sources, including clinical trials, post-marketing surveillance, spontaneous reports, and literature reviews.
A key component of this safety data is the Individual Case Safety Report (ICSR). An ICSR is a structured report containing information about a suspected adverse event or adverse reaction in an individual patient, along with relevant details such as the medicinal product, patient characteristics, reporter information, and clinical circumstances. Drug safety databases are used to receive, validate, process, assess, and report ICSRs as part of the pharmacovigilance workflow.
What is an adverse event reporting system?
An adverse event reporting system is a system used to collect, manage, process, and evaluate adverse event reports associated with medicinal products. These reports may be received from healthcare professionals, patients, consumers, product manufacturers, and other sources, depending on the applicable reporting framework.
When an individual report contains the required information for a valid safety case, it may be managed as an Individual Case Safety Report (ICSR) within a pharmacovigilance system. ICSRs form a core part of post-marketing safety surveillance and can be submitted to relevant regulatory authorities in accordance with applicable requirements.
How are adverse events/reactions characterised?
Adverse events/reactions can be classified by seriousness as serious or non-serious.
-
Serious Adverse Events
A serious adverse event is an event that:
- results in death,
- is life-threatening,
- requires inpatient hospitalisation or prolongation of existing hospitalisation,
- results in persistent or significant disability or incapacity,
- is a congenital anomaly/birth defect,
- or is otherwise medically important.
-
Non-Serious Adverse Events
A non-serious AE is an adverse event that does not meet any of the regulatory criteria for a serious adverse event (SAE). Such events are typically non-serious only when none of the regulatory seriousness criteria are met.
Separately, suspected adverse reactions can be assessed for expectedness as expected or unexpected.
-
Expected Adverse Reaction
The nature and severity are consistent with the applicable product information used for the expectedness assessment.
-
Unexpected Adverse Reaction
The nature or severity is not consistent with the applicable product information used for the expectedness assessment.
E.g., if the reference safety information lists headache but a patient develops seizures, and seizures are not listed or described in the applicable product information, the event may be considered unexpected.
What is the significance of adverse event reporting system?
An adverse event reporting system provides an important evidence base for evaluating the safety of medicines throughout their lifecycle. The significance includes:
-
Improved patient safety
Adverse event monitoring helps in taking proactive measures to mitigate the impact caused by medicines. This safety monitoring does not end after a product is approved. Adverse event reporting system supports ongoing evaluation of a medicine’s benefit-risk profile throughout its lifecycle.
-
Regulatory action
When a safety concern is identified, regulatory agencies like the EMA and FDA take actions such as updating product labelling, issuing a safety concern and, in serious cases, withdrawing a product.
-
Improved drug development
Analysis of adverse event reports helps researchers and pharmaceutical companies understand how a drug performs. They identify patient populations across a broader range with potential safety concerns that may not have been fully evident during clinical development.
-
Supports benefit-risk assessment
Continuous analysis of adverse event data helps developers and regulators evaluate whether the benefits of a medicine continue to outweigh its risks.
Who can be the source of an adverse event report?
Adverse events are reported by:
- Healthcare Professionals – Physicians, pharmacists, nurses, and other healthcare professionals may report suspected adverse events observed in patients.
- Patients/Consumers – Patients, carers, and consumers can report adverse events they experience or observe.
Here, Marketing Authorisation Holders (MAHs)/Pharmaceutical Companies collect safety information from various sources and are responsible for processing and submitting reportable ICSRs to the relevant regulatory authorities.
The regulatory authorities or National Competent Authorities (NCAs) receive safety reports from healthcare professionals, patients, MAHs, and other sources and maintain pharmacovigilance systems for monitoring medicine safety.
Challenges in adverse event reporting
The challenges in adverse event reporting span across:
-
Inconsistent reporting of adverse events
Safety information received from patients and other reporters may sometimes be incomplete, inconsistent, or unverified. Reported events may lack important clinical details, contain unclear timelines, or reflect symptoms that could have multiple possible causes, including the underlying disease or concomitant conditions. This makes clinical assessment, medical review, and appropriate follow-up essential to clarify the case, assess its clinical significance and relationship to the medicinal product, and support accurate safety evaluation and regulatory decision-making.
-
Challenges in spontaneous reporting
Most adverse events are registered by patients or health care professionals. The major drawback of this is that events may not be recognised as medicine-related, reporting procedures may be unclear, or reporting may not occur for other practical reasons. They may see these adverse events as unrelated to the medicine or may lack time to report.
-
Incomplete information
An ICSR may contain incomplete or inconsistent information, such as the patient’s age, dose, treatment duration, medical history, concomitant medicines, laboratory results, or clinical outcome. Missing information can make it more difficult for pharmacovigilance professionals to assess the case, determine seriousness and expectedness, evaluate causality, and establish whether the report meets regulatory requirements for a valid ICSR.
Minimum criteria for an ICSR are the following:
– AE/ADR or other observation
– Suspect/interacting medicinal product
– Identifiable patient
– Identifiable reporter
-
Underreporting
Many adverse events are never reported because patients or healthcare professionals may not recognise the event as drug-related. They may be unaware of reporting procedures or may not have enough time to submit a report.
-
Difficulty establishing causality
The presence of an adverse event does not necessarily mean that the medicine caused it. Other factors, including underlying disease, other medicines, or patient characteristics, may contribute.
-
Integration between systems
Integration between systems like clinical data management systems (CDMS), product performance systems, clinical coding applications, and CROs is the cornerstone of integrated data analysis. There are integration challenges across heterogeneous clinical, safety, and regulatory systems and standards such as ICH E2B(R3).
Conclusion
Drug safety databases and AERS are essential to modern pharmacovigilance. They collect, assess, and monitor safety information. They help organisations identify potential signals, protect patients, maintain regulatory compliance, and continuously evaluate a medicine’s benefit–risk profile.
However, inconsistent data, causality challenges, and fragmented systems can limit their effectiveness. AI supports literature screening, duplicate identification and signal detection with appropriate validation and human oversight.
At pharma-ai.de, we explore practical, compliant, and human-centred AI solutions that strengthen drug safety operations and support faster, better-informed pharmacovigilance decisions.
Learn more about how AICSR supports compliant ICSR workflows.